Immunogenicity of COVID-19 vaccines in KCMH health care workers
- Conditions
- COVID-19
- Registration Number
- TCTR20210325003
- Lead Sponsor
- Ratchadapiseksompotch Research Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
1.The subject is aged > 18 years
2.Subjects had no history of COVID-19 vaccination before enrollment
3.Subjects who can comply with trial procedures and are available for the duration of follow-up
Exclusion Criteria
1.Subjects who received any other vaccines within 1 month prior to enrollment
2.Subjects who received blood or blood product or immunoglobulin within 3 months prior to enrollment
3.Subjects participating in any clinical trial with COVID-19 immunogenicity
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Seroconversion rate by neutralizing antibody 4 weeks, 6 and 12 months after complete immunization cPass SARS-CoV-2 Neutralization Antibody Detection Kit GenScript
- Secondary Outcome Measures
Name Time Method Seroconversion rate by IgG 4 weeks, 6 and 12 months after complete immunization Enzyme-Linked Immunosorbent Assay (ELISA) ,Immunogenicity to variant strain 4 weeks after complete immunization Plaque reduction neutralization test PRNT,Immunogenicity by T cell 4 weeks after complete immunization IFN gamma ELISPOT